JAJeremy M. Aymard

Jeremy M. Aymard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeremy M. Aymard has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating

    by Mona Kamal, David I. Rosenthal, Aakash Batra, Stefania Volpe, Baher Elgohari, Ryan P. Goepfert, Adam S. Garden, Jack Phan, Salman Eraj, Amy Dursteler, et al.


  • Long‐term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies

    by Matthew A. Tyler, Abdallah S.R. Mohamed, Joshua B. Smith, Jeremy M. Aymard, Clifton D. Fuller, Jack Phan, Steven J. Frank, Renata Ferrarotto, Michael E. Kupferman, Ehab Y. Hanna, et al.

    Objective: To evaluate long‐term global and site‐specific health‐related quality of life (HRQoL) in patients treated for sinonasal and nasopharyngeal malignancies.Study Design: Cross‐sectional.Methods: One hundred fourteen patients with sinonasal and nasopharyngeal malignancies received surgery, radiation, systemic chemotherapy, or a combination thereof, with curative intent. Validated global ([EuroQol‐5D] Visual Analogue Scale [EQ‐5D VAS]) and disease‐specific instruments (MD Anderson Symptom Inventory–Head and Neck [MDASI‐HN], Anterior Skull Base Questionnaire [ASBQ]) were administered to patients who were both free of disease and had completed treatment at least 12 months previously. Associations between instruments, instrument domains, and specific clinical parameters were analyzed.Results: The median age was 55 years. The mean EQ‐5D VAS, MDASI‐22 composite score, and ASBQ score were 74 (standard deviation [SD] 21), 48 (SD 36), and 130 (SD 27), respectively. The most frequently reported high‐severity items in MDASI‐HN were dry mouth and difficulty tasting food. The most frequently reported high‐severity items in ASBQ were difficulty with smell and nasal secretions. Advanced Tumor (T) classification was associated with worse overall ASBQ sum score (P = 0.02). ASBQ performance at home and MDASI‐HN drowsy symptom items independently predicted worse global HRQoL as measured by the EQ‐5D VAS (P < 0.001).Conclusion: Global HRQoL for survivors of sinonasal and nasopharyngeal malignancies after multimodality treatment approximates that of the U.S. population for the same age group. ASBQ and MDASI‐HN correlate well with global HRQoL outcomes as measured by EQ‐5D VAS. MDASI‐HN and ASBQ elicited unique symptoms, highlighting the complex symptom burden experienced by these patients. Further studies should identify patients predisposed to reduced long‐term QOL.Level of Evidence: 3 Laryngoscope, 130:86–93, 2020


  • Open Access

    Machine Learning Applications in Head and Neck Radiation Oncology: Lessons From Open-Source Radiomics Challenges

    by Hesham Elhalawani, Timothy A Lin, Stefania Volpe, Abdallah S R Mohamed, Aubrey L White, James Zafereo, Andrew J Wong, Joel E Berends, Shady AboHashem, Bowman Williams, et al.

    Radiomics leverages existing image datasets to provide non-visible data extraction via image post-processing, with the aim of identifying prognostic, and predictive imaging features at a sub-region of interest level. However, the application of radiomics is hampered by several challenges such as lack of image acquisition/analysis method standardization, impeding generalizability. As of yet, radiomics remains intriguing, but not clinically validated. We aimed to test the feasibility of a non-custom-constructed platform for disseminating existing large, standardized databases across institutions for promoting radiomics studies. Hence, University of Texas MD Anderson Cancer Center organized two public radiomics challenges in head and neck radiation oncology domain. This was done in conjunction with MICCAI 2016 satellite symposium using Kaggle-in-Class, a machine-learning and predictive analytics platform. We drew on clinical data matched to radiomics data derived from diagnostic contrast-enhanced computed tomography (CECT) images in a dataset of 315 patients with oropharyngeal cancer. Contestants were tasked to develop models for (i) classifying patients according to their human papillomavirus status, or (ii) predicting local tumor recurrence, following radiotherapy. Data were split into training, and test sets. Seventeen teams from various professional domains participated in one or both of the challenges. This review paper was based on the contestants' feedback; provided by 8 contestants only (47%). Six contestants (75%) incorporated extracted radiomics features into their predictive model building, either alone (n = 5; 62.5%), as was the case with the winner of the “HPV” challenge, or in conjunction with matched clinical attributes (n = 2; 25%). Only 23% of contestants, notably, including the winner of the “local recurrence” challenge, built their model relying solely on clinical data. In addition to the value of the integration of machine learning into clinical decision-making, our experience sheds light on challenges in sharing and directing existing datasets toward clinical applications of radiomics, including hyper-dimensionality of the clinical/imaging data attributes. Our experience may help guide researchers to create a framework for sharing and reuse of already published data that we believe will ultimately accelerate the pace of clinical applications of radiomics; both in challenge or clinical settings.


  • Open Access

    Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients

    by M. D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group, Hesham Elhalawani, Aasheesh Kanwar, Abdallah S. R. Mohamed, Aubrey White, James Zafereo, Andrew Wong, Joel Berends, Shady Abohashem, Bowman Williams, et al.

    Radiomics is one such “big data” approach that applies advanced image refining/data characterization algorithms to generate imaging features that can quantitatively classify tumor phenotypes in a non-invasive manner. We hypothesize that certain textural features of oropharyngeal cancer (OPC) primary tumors will have statistically significant correlations to patient outcomes such as local control. Patients from an IRB-approved database dispositioned to (chemo)radiotherapy for locally advanced OPC were included in this retrospective series. Pretreatment contrast CT scans were extracted and radiomics-based analysis of gross tumor volume of the primary disease (GTVp) were performed using imaging biomarker explorer (IBEX) software that runs in Matlab platform. Data set was randomly divided into a training dataset and test and tuning holdback dataset. Machine learning methods were applied to yield a radiomic signature consisting of features with minimal overlap and maximum prognostic significance. The radiomic signature was adapted to discriminate patients, in concordance with other key clinical prognosticators. 465 patients were available for analysis. A signature composed of 2 radiomic features from pre-therapy imaging was derived, based on the Intensity Direct and Neighbor Intensity Difference methods. Analysis of resultant groupings showed robust discrimination of recurrence probability and Kaplan-Meier-estimated local control rate (LCR) differences between “favorable” and “unfavorable” clusters were noted.


  • Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors

    by Mona Kamal, David I. Rosenthal, Stefania Volpe, Ryan P. Goepfert, Adam S. Garden, Katherine A. Hutcheson, Karine A. Al Feghali, Mohamed Ahmed Mohamed Meheissen, Salman A. Eraj, Amy E. Dursteler, et al.


  • Open Access

    Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old

    by MD Anderson Head and Neck Cancer Symptom Working Group, Salman A. Eraj, Mona K. Jomaa, Crosby D. Rock, Abdallah S. R. Mohamed, Blaine D. Smith, Joshua B. Smith, Theodora Browne, Luke C. Cooksey, Bowman Williams, et al.

    In the original publication [1] the name of author Jeremy M. Aymard was spelled wrong. The original article was updated to rectify this error.

  • Open Access

    Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old

    by MD Anderson Head and Neck Cancer Symptom Working Group, Salman A. Eraj, Mona K. Jomaa, Crosby D. Rock, Abdallah S. R. Mohamed, Blaine D. Smith, Joshua B. Smith, Theodora Browne, Luke C. Cooksey, Bowman Williams, et al.

    Given the potential for older patients to experience exaggerated toxicity and symptoms, this study was performed to characterize patient reported outcomes in older patients following definitive radiation therapy (RT) for oropharyngeal cancer (OPC). Cancer-free head and neck cancer survivors (>6 months since treatment completion) were eligible for participation in a questionnaire-based study. Participants completed the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN). Those patients ≥65 years old at treatment for OPC with definitive RT were included. Individual and overall symptom severity and clinical variables were analyzed. Of the 79 participants analyzed, 82% were male, 95% white, 41% T3/4 disease, 39% RT alone, 27% induction chemotherapy, 52% concurrent, and 18% both, and 96% IMRT. Median age at RT was 71 yrs. (range: 65–85); median time from RT to MDASI-HN was 46 mos. (2/3 > 24 mos.). The top 5 MDASI-HN items rated most severe in terms of mean (±SD) ratings (0–10 scale) were dry mouth (3.48 ± 2.95), taste (2.81 ± 3.29), swallowing (2.59 ± 2.96), mucus in mouth/throat (2.04 ± 2.68), and choking (1.30 ± 2.38) reported at moderate-severe levels (≥5) by 35, 29, 29, 18, and 13%, respectively. Thirty-nine % reported none (0) or no more than mild (1–4) symptoms across all 22 MDASI-HN symptoms items, and 38% had at least one item rated as severe (≥7). Hierarchical cluster analysis resulted in 3 patient groups: 1) ~65% with ranging from none to moderate symptom burden, 2) ~35% with moderate-severe ratings for a subset of classically RT-related symptoms (e.g. dry mouth, mucus, swallowing) and 3) 2 pts. with severe ratings of most items. The overall long-term symptom burden seen in this older OPC cohort treated with modern standard therapy was largely favorable, yet a higher symptom group (~35%) with a distinct pattern of mostly local and classically RT-related symptoms was identified.


  • Open Access

    Matched computed tomography segmentation and demographic data for oropharyngeal cancer radiomics challenges

    by Miccai/M.D. Anderson Cancer Center Head, Neck Quantitative Imaging Working Group, Hesham Elhalawani, Abdallah S.R. Mohamed, Aubrey L. White, James Zafereo, Andrew J. Wong, Joel E. Berends, Shady AboHashem, Bowman Williams, et al.

    Cancers arising from the oropharynx have become increasingly more studied in the past few years, as they are now epidemic domestically. These tumors are treated with definitive (chemo)radiotherapy, and have local recurrence as a primary mode of clinical failure. Recent data suggest that ‘radiomics’, or extraction of image texture analysis to generate mineable quantitative data from medical images, can reflect phenotypes for various cancers. Several groups have shown that developed radiomic signatures, in head and neck cancers, can be correlated with survival outcomes. This data descriptor defines a repository for head and neck radiomic challenges, executed via a Kaggle in Class platform, in partnership with the MICCAI society 2016 annual meeting.These public challenges were designed to leverage radiomics and/or machine learning workflows to discriminate HPV phenotype in one challenge (HPV status challenge) and to identify patients who will develop a local recurrence in the primary tumor volume in the second one (Local recurrence prediction challenge) in a segmented, clinically curated anonymized oropharyngeal cancer (OPC) data set.